Manzo Pharmaceuticals, Inc.
MNZO · OTC
9/30/2005 | 12/31/2004 | 9/30/2004 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | -$37 | $65 |
| Gross Profit | $0 | $37 | -$65 |
| % Margin | – | – | – |
| R&D Expenses | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 |
| SG&A Expenses | $617 | $864 | $659 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $3 | $30 |
| Operating Expenses | $617 | $867 | $689 |
| Operating Income | -$617 | -$830 | -$754 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $617 | $830 | $754 |
| Pre-Tax Income | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$1,225 | -$1,035 | -$1,019 |
| % Margin | – | – | – |
| EPS | -0.2 | -0.298 | -0.3 |
| % Growth | 32.8% | 0.8% | – |
| EPS Diluted | -0.2 | -0.298 | -0.3 |
| Weighted Avg Shares Out | 5,245 | 3,478 | 3,491 |
| Weighted Avg Shares Out Dil | 5,245 | 3,478 | 3,491 |
| Supplemental Information | – | – | – |
| Interest Income | $0 | $0 | $0 |
| Interest Expense | $0 | $188 | $0 |
| Depreciation & Amortization | $28 | $0 | $30 |
| EBITDA | $28 | -$2,837 | -$65 |
| % Margin | – | – | – |